Showing results (91-100 of 155) with videos related to

Sort By:
Pageof 16
Eclinicalmedicine|August 20, 2024
Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trialAshwath Gurumurthi, Collin K Chin, Lei Feng, et al.
Practical Radiation Oncology|July 10, 2026
Safety of concurrent radiation therapy with the antibody-drug conjugate polatuzumab vedotin in relapsed or refractory aggressive B-cell lymphomasSophie T Melancon, Ethan B Wang, Penny Q Fang, et al.
Leukemia & Lymphoma|November 10, 2017
Myeloid/lymphoid neoplasms with FGFR1 rearrangementPaolo Strati, Guilin Tang, Dzifa Y Duose, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Cancer|April 9, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025Alexey V Danilov, Catherine C Coombs, Tycel Phillips, et al.
British Journal of Haematology|January 12, 2026
Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphomaKunhwa Kim, Rahul Shah, Amy Ayers, et al.
Leukemia & Lymphoma|August 26, 2021
A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphomaHua-Jay J Cherng, Hubert H Chuang, Raphael Steiner, et al.
Haematologica|October 12, 2019
Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphomaPaolo Strati, Mohamed Amin Ahmed, Nathan H Fowler, et al.
Advances in Radiation Oncology|July 14, 2023
Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of LymphomaSusan Y Wu, Penny Q Fang, Ethan B Wang, et al.
The Lancet. Haematology|August 30, 2016
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trialPaolo Strati, Mark Lanasa, Timothy G Call, et al.
Pageof 16